TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2025-03-20
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $1.60M, a 45.45% increase from fiscal 2023.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $1.10M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2024-12-31 | $1.60M 10-K · filed 2025-03-20 |
| 2023-12-31 | $1.10M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |